Evidence map›Paper›PMID 36129297›Full record

ArticlemBio2022

The Heptaprenyl Diphosphate Synthase (Coq1) Is the Target of a Lipophilic Bisphosphonate That Protects Mice against Toxoplasma gondii Infection.

Melissa A Sleda, Zhu-Hong Li, Ranjan Behera, Baihetiya Baierna, Catherine Li, Jomkwan Jumpathong, Satish R Malwal, Makoto Kawamukai, Eric Oldfield, Silvia N J Moreno

Open access · goldAbstract read
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Legacy 4(1ACS infectious diseases · 2026
    Article
  2. Article
  3. First In Silico Study of TwoInternational journal of molecular sciences · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. TheeLife · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Melissa A Sleda *Center for Tropical and Emerging Global Diseases, University of Georgiagrid.213876.9, Athens, Georgia, USA.
Zhu-Hong Li *Center for Tropical and Emerging Global Diseases, University of Georgiagrid.213876.9, Athens, Georgia, USA.
Ranjan BeheraCenter for Tropical and Emerging Global Diseases, University of Georgiagrid.213876.9, Athens, Georgia, USA.
Baihetiya BaiernaCenter for Tropical and Emerging Global Diseases, University of Georgiagrid.213876.9, Athens, Georgia, USA.
Catherine LiCenter for Tropical and Emerging Global Diseases, University of Georgiagrid.213876.9, Athens, Georgia, USA.
Jomkwan JumpathongDepartment of Life Sciences, Faculty of Life and Environmental Sciences, Shimane Universitygrid.411621.1, Matsue, Japan.
Satish R MalwalDepartment of Chemistry, University of Illinois at Urbana Champaign, Urbana, Illinois, USA.
Makoto KawamukaiDepartment of Life Sciences, Faculty of Life and Environmental Sciences, Shimane Universitygrid.411621.1, Matsue, Japan.
Eric OldfieldDepartment of Chemistry, University of Illinois at Urbana Champaign, Urbana, Illinois, USA.
Silvia N J MorenoCenter for Tropical and Emerging Global Diseases, University of Georgiagrid.213876.9, Athens, Georgia, USA.ORCID 0000-0002-2041-6295
University of Georgia · USShimane University · JPUniversity of Illinois Urbana-Champaign · US

Funding

Training in Tropical and Emerging Global Diseases - SupplementT32AI060546 · NIAID · UNIVERSITY OF GEORGIA (UGA) · PI Silvia N Moreno, Vasant Muralidharan · 2004 to 2026
$5.1M
Validation of the ubiquinone synthesis pathway of Toxoplasma gondii as a novel drug targetR01AI169846 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2022 to 2025
$2.1M
Targeting Host and Apicomplexan Isoprenoid PathwaysR33AI102254 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2014 to 2016
$1.3M
Anti-Toxoplasma isoprenoid pathway inhibitors and the host immune responseR21AI147661 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2020 to 2021
$415k
Targeting Host and Apicomplexan Isoprenoid PathwaysR21AI102254 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2012 to 2013
$408k
NIAID NIH HHS R01 AI169846NIAID NIH HHS R21 AI102254NIAID NIH HHS R21 AI147661NIAID NIH HHS R33 AI102254NIAID NIH HHS T32 AI060546
6 · The paper itself

Abstract

Prenyldiphosphate synthases catalyze the reaction of allylic diphosphates with one or more isopentenyl diphosphate molecules to form compounds such as farnesyl diphosphate, used in, e.g., sterol biosynthesis and protein prenylation, as well as longer "polyprenyl" diphosphates, used in ubiquinone and menaquinone biosynthesis. Quinones play an essential role in electron transport and are associated with the inner mitochondrial membrane due to the presence of the polyprenyl group. In this work, we investigated the synthesis of the polyprenyl diphosphate that alkylates the ubiquinone ring precursor in Toxoplasma gondii, an opportunistic pathogen that causes serious disease in immunocompromised patients and the unborn fetus. The enzyme that catalyzes this early step of the ubiquinone synthesis is Coq1 (TgCoq1), and we show that it produces the C35 species heptaprenyl diphosphate. TgCoq1 localizes to the mitochondrion and is essential for

Indexed as

ToxoplasmaToxoplasmosisAlkyl and Aryl TransferasesAnimalsDiphosphatesDiphosphonatesMiceSterolsUbiquinoneVitamin K 2Alkyl and Aryl TransferasesDiphosphatesDiphosphonatesSterolstrans-hexaprenyltranstransferaseUbiquinoneUbiquinone Q1Vitamin K 2bisphosphonateisoprenoidsmitochondriaToxoplasma gondiiubiquinone

Identifiers

PMID36129297
PMCPMC9600589
OpenAlexW4296707333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.